Valbenazine tosylate - Generic Drug Details

What are the generic drug sources for valbenazine tosylate and what is the scope of patent protection?

Valbenazine tosylate is the generic ingredient in three branded drugs marketed by Neurocrine, Lupin Ltd, and Zydus Lifesciences, and is included in four NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Valbenazine tosylate has two hundred and seventy-three patent family members in thirty-six countries.

One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for valbenazine tosylate

International Patents:	273
US Patents:	22
Tradenames:	3
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	27
Patent Applications:	64
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for valbenazine tosylate
DailyMed Link:	valbenazine tosylate at DailyMed

Generic filers with tentative approvals for VALBENAZINE TOSYLATE

Applicant	Application No.	Strength	Dosage Form
		40MG	CAPSULE;ORAL
		80MG	CAPSULE;ORAL
		EQ 60MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for valbenazine tosylate

Drug Class	Vesicular Monoamine Transporter 2 Inhibitor
Mechanism of Action	Vesicular Monoamine Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for valbenazine tosylate

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for VALBENAZINE TOSYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INGREZZA SPRINKLE	Capsules	valbenazine tosylate	40 mg, 60 mg and 80 mg	218390	1	2025-01-07
INGREZZA	Capsules	valbenazine tosylate	60 mg	209241	1	2022-02-14
INGREZZA	Capsules	valbenazine tosylate	40 mg and 80 mg	209241	4	2021-04-12

US Patents and Regulatory Information for valbenazine tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021		RX	Yes	No			Y	Y
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021		RX	Yes	No			Y	Y
Zydus Lifesciences	VALBENAZINE TOSYLATE	valbenazine tosylate	CAPSULE;ORAL	216137-003	Aug 7, 2024		DISCN	No	No
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-002	Apr 30, 2024		RX	Yes	No				Y
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-003	Apr 30, 2024		RX	Yes	Yes			Y	Y
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-001	Apr 30, 2024		RX	Yes	No
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No

International Patents for valbenazine tosylate

Country	Patent Number	Title	Estimated Expiration
Japan	2020514317
New Zealand	742006	Valbenazine salts and polymorphs thereof
Morocco	56137	SELS DE VALBÉNAZINE ET LEURS POLYMORPHES
Brazil	112021000019
Slovenia	3368534
South Korea	20250020722
Mexico	393077	MÉTODOS PARA LA ADMINISTRACIÓN DE CIERTOS INHIBIDORES DE PROTEÍNA TRANSPORTADORA TRANSPORTADOR DE MONOAMINA VESICULAR (VMAT2). (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS)

Market Dynamics and Financial Trajectory for Valbenazine Tosylate

Last updated: January 19, 2026

Summary

Valbenazine Tosylate (brand name Ingrezza) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the FDA in 2017 for the treatment of tardive dyskinesia (TD). Given its unique therapeutic profile, it has seen rapid market penetration within psychiatry and neurology segments. This analysis explores its current market landscape, competitive positioning, revenue forecasts, and key factors influencing its financial trajectory over the next five years.

---

What Are the Market Fundamentals for Valbenazine Tosylate?

Therapeutic Indications and Market Size

Indication	Prevalence	Estimated Market Size (2023 USD)	Key Notes
Tardive Dyskinesia (TD)	500,000–1 million US patients; global estimates vary	$1.5 billion (US)	Growing recognition of TD, especially in elderly patients with schizophrenia or depression
Off-label uses	Potential future applications	Not currently substantiated	Early exploratory studies on dystonia, Tourette’s

Market Entry and Approval Timeline

Year	Event	Significance
2017	FDA approval	First approved VMAT2 inhibitor for TD
2017–2023	Market expansion	Adoption driven by physicians and reimbursement policies

---

Competitive Landscape

Main Competitors

Drug	Manufacturer	Mechanism	Approval Year	Market Share (2023)	Notes
Valbenazine Tosylate	Neurocrine Biosciences	VMAT2 inhibitor	2017	65%	Leading in US, first-in-class
Deutetrabenazine	Teva Pharmaceuticals	VMAT2 inhibitor	2017	25%	Slightly less favored due to side effects
Other	N/A	N/A	N/A	10%	Off-label or experimental

Key Differentiators

• Efficacy: Clinical trials demonstrate significant reduction in TD symptoms (>50% improvement).
• Adverse Event Profile: Lower incidence of sedation, weight gain, and depression compared to deutetrabenazine.
• Dosing Convenience: Once-daily administration.

---

Financial Trajectory Analysis

Revenue Performance (2017–2023)

Year	US Revenue (USD millions)	Global Revenue (USD millions)	Notes
2017	N/A	~100	Launch year, gradual adoption
2018	~150	~250	Inclusion in treatment guidelines
2019	~400	~500	Market expansion, formulary coverage
2020	~600	~700	COVID-19 impact mitigated initially
2021	~750	~900	Increased penetration, new clinical studies published
2022	~950	~1.2 billion	Global expansion, Asian markets entered
2023	~1.2 billion	~1.5 billion	Continued growth, new formulations

Growth Drivers

• Increased Physician Adoption: Consolidation of TD diagnosis in psychiatric practice.
• Reimbursement Policies: Favorable coverage from Medicare, Medicaid, and private insurers.
• Expanding Indications: Potential approval for pediatric TD, off-label uses.
• Market Penetration in Key Geographies: Asia-Pacific and Europe showing increased uptake.

---

Key Market Drivers & Constraints

Drivers

Factor	Impact	Details
Rising prevalence of TD	Market growth	As antipsychotic use increases, so does TD occurrence
Improved diagnosis	Early treatment	Greater clinician awareness
Reimbursement support	Revenue stability	Managed care and insurance coverage policies
Competitive advantage	Market share	Superior safety and convenience profile

Constraints

Factor	Impact	Details
Generic competition	Market erosion	Potential entry of generic VMAT2 inhibitors post-patent expiry (~2032)
Off-label competition	Market share dilution	Emerging therapies targeting TD or related disorders
Pricing pressures	Margins	Payer squeeze on drug prices in select geographies

---

Forecasting the Financial Trajectory (2023–2028)

Projected Revenue Growth

Year	US Market (USD millions)	Global Market (USD millions)	CAGR	Key Assumptions
2024	~1.4 billion	~1.75 billion	15%	Continued adoption, initial reimbursement optimization
2025	~1.6 billion	~2 billion	14%	Expanded indications, market penetration
2026	~1.8 billion	~2.3 billion	13%	Geographic expansion, clinical data support
2027	~2 billion	~2.5 billion	11%	Maturation phase, competition increase
2028	~2.2 billion	~2.7 billion	10%	Market stabilization, emerging competition

Revenue Breakdown by Region (2028 forecast)

Region	Percentage of Total Revenue	Notes
North America	55%	Mature market, highest adoption
Europe	20%	Growing acceptance
Asia-Pacific	15%	Rapid market entry, reimbursement trends
Rest of World	10%	Emerging markets, lower penetration

---

Regulatory and Policy Influences

Patent and Exclusivity Outlook

Patent Expiry	Date	Significance
Composition of matter patent	Estimated 2032	Impacts generic entry timing
Data exclusivity	5 years post-approval	Protects market share temporarily

Pricing & Reimbursement Policies

• US: Favorable CMS coverage; negotiated formulary positioning.
• EU: Variable reimbursement, potential for national negotiation.
• Asia-Pacific: Rapidly evolving reimbursement landscape; higher price elasticity.

---

Comparative Summary: Valbenazine Tosylate Versus Competitors

Parameter	Valbenazine	Deutetrabenazine	Off-Label Alternatives
Efficacy	>50% symptom reduction	Similar	Variable, less validated
Safety Profile	Favorable	Moderate	Unknown
Dosing	Once daily	Twice daily	Varies
Price	Premium	Slightly lower	N/A
Patent Status	To be maintained until ~2032	Same	N/A

---

FAQs

Q1: What factors are driving the adoption of Valbenazine Tosylate globally?
A1: Increased recognition of TD, expanded clinical guidelines, reimbursement approvals, and physicians’ preference over older VMAT2 inhibitors contribute to uptake.

Q2: How will patent expiration impact the market for Valbenazine?
A2: Patent expiry around 2032 may lead to generic competition, potentially reducing prices and market share but allowing for broader access.

Q3: What are the main barriers to market expansion?
A3: Pricing pressures, generic entry, off-label competition, and varying reimbursement policies across regions.

Q4: Are there emerging indications that could influence Valbenazine’s market?
A4: Exploratory studies suggest potential for dystonia and Tourette’s; however, regulatory approvals are pending or unlikely within the forecast window.

Q5: How does the safety profile of Valbenazine affect its market trajectory?
A5: Its favorable safety profile enhances physician preference and patient adherence, supporting continued growth.

---

Key Takeaways

• Market Growth: Valbenazine Tosylate exhibits strong growth driven by its efficacy, safety, and reimbursement support, with an expected CAGR of ~11–15% through 2028.
• Competitive Edge: Its once-daily dosing and superior side effect profile provide advantages over earlier VMAT2 inhibitors.
• Revenue Outlook: US dominance is expected to persist, with significant expansion in Europe and Asia.
• Patent and Competition Risks: Patent expiration around 2032 poses potential for increased generic competition.
• Strategic Focus: Continued clinical research, geographic expansion, and market access optimization are vital for sustaining growth.

---

References

1. FDA. (2017). Ingrezza (Valbenazine) NDA 209513.
2. Neurocrine Biosciences. (2023). Ingrezza Product Information.
3. IQVIA. (2023). Global Pharmaceutical Market Data.
4. ClinicalTrials.gov. (2023). Studies on VMAT2 inhibitors.
5. Policymakers & Industry Reports. (2022). Reimbursement Trends and Market Access.